Drug intelligence / Profile preview

Satiete

Development stage: Preclinical
Lead developer: Wellness International Network

Overview

Satiete is an herbal product used for weight reduction. It is listed in the Physicians' Desk Reference for Nonprescription Drugs and Dietary Supplements. In a retrospective analysis, patients treated with a combination of prescription phentermine and Satiete for a mean of 12.4 weeks lost a mean of 0.87 lb/wk, with 87% losing at least 0.5 lb/wk. No significant adverse reactions were noted.

Brand names: Satiete

Beyond the preview

Go deeper on Satiete.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Satiete.

Explore the full profile